168 related articles for article (PubMed ID: 6502472)
1. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
Lima JJ; Haughey DB; Leier CV
J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
Lima JJ; Boudoulas H; Shields BJ
Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
Le Corre P; Gibassier D; Sado P; Le Verge R
Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
[TBL] [Abstract][Full Text] [Related]
4. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of disopyramide in normal volunteers using unbound concentration.
Braun J; Sörgel F; Gluth WP; Oie S
Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of disopyramide.
Siddoway LA; Woosley RL
Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
[TBL] [Abstract][Full Text] [Related]
7. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
Lima JJ; Boudoulas H; Blanford M
J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
Landmark K; Bredesen JE; Thaulow E; Simonsen S; Amlie JP
Eur J Clin Pharmacol; 1981 Feb; 19(3):187-92. PubMed ID: 7215416
[TBL] [Abstract][Full Text] [Related]
9. Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
Giacomini KM; Blaschke TF
Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():42-8. PubMed ID: 6705426
[TBL] [Abstract][Full Text] [Related]
10. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
Haughey DB; Lima JJ
Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of disopyramide in decreased hepatic function.
Bonde J; Graudal NA; Pedersen LE; Balsløv S; Angelo HR; Svendsen TL; Kampmann JP
Eur J Clin Pharmacol; 1986; 31(1):73-7. PubMed ID: 3780831
[TBL] [Abstract][Full Text] [Related]
12. Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?
Braun J; Sörgel F; Gluth WP; Oie S
Eur J Clin Pharmacol; 1988; 35(3):313-7. PubMed ID: 3181285
[TBL] [Abstract][Full Text] [Related]
13. Human pharmacokinetics and metabolism of disopyramide enantiomers.
Le Corre P; Gibassier D; Sado P; Le Verge R
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
Bonde J; Angelo HR; Bødtker S; Svendsen TL; Kampmann JP
Acta Pharmacol Toxicol (Copenh); 1985 Apr; 56(4):278-82. PubMed ID: 4024955
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias.
Chiba K; Koike K; Nakamoto M; Echizen H; Ishizawa A; Ishizaki T
Ther Drug Monit; 1992 Apr; 14(2):112-8. PubMed ID: 1585394
[TBL] [Abstract][Full Text] [Related]
16. The influence of age and smoking on the elimination of disopyramide.
Bonde J; Pedersen LE; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
Br J Clin Pharmacol; 1985 Nov; 20(5):453-8. PubMed ID: 4074615
[TBL] [Abstract][Full Text] [Related]
17. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.
Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE
Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959
[TBL] [Abstract][Full Text] [Related]
18. Disopyramide pharmacokinetics during recovery from myocardial infarction.
Bryson SM; Cairns CJ; Whiting B
Br J Clin Pharmacol; 1982 Mar; 13(3):417-21. PubMed ID: 7059444
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
Aitio ML; Allonen H; Kanto J; Mäntylä R
Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics and protein binding of disopyramide in pigs.
Pedersen LE; Hermansen K; Olesen HP; Rasmussen SN
Acta Pharmacol Toxicol (Copenh); 1986 Apr; 58(4):282-8. PubMed ID: 3716823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
